Cet article est une Preprint
Les preprints sont des rapports de recherche préliminaires qui n'ont pas été certifiés par l’évaluation par les pairs. Ils ne devraient pas être considérés comme guidant la pratique clinique ou les comportements liés à la santé et ne devraient pas être rapportés dans les médias comme des informations établies.
Les preprints publiées en ligne permettent aux auteurs de recevoir des commentaires rapidement, et toute la communauté scientifique peut évaluer indépendamment le travail et répondre en conséquence. Ces commentaires sont publiés avec les preprints que quiconque peut lire et servir d’évaluation post-publication.
Cost-effectiveness of the second COVID-19 booster vaccination in the United States (preprint)
medrxiv; 2022.
Preprint
Dans Anglais
| medRxiv | ID: ppzbmed-10.1101.2022.12.28.22283986
ABSTRACT
ABSTRACT Background:
On March 29, 2022, the United States (US) authorized the second booster dose of COVID-19 vaccine for individuals aged 50 years and older. To date, the cost-effectiveness of the second booster strategy remains unassessed.Methods:
We developed a decision-analytic SEIR-Markov model by five age groups (0-4yrs with 18,827,338 individuals, 5-11yrs with 28,584,443 individuals, 12-17yrs with 26,154,652 individuals, 18-49yrs with 138,769,369 individuals, and 50+yrs with 119,557,943 individuals) to evaluate the cost-effectiveness of the second COVID-19 booster vaccination (administered 4 months after the first booster dose) over an evaluation period of 180 days in the US, from a healthcare system perspective.Results:
Implementing the second booster strategy among individuals aged 50+ years would cost US$807 million but reduce direct medical care costs by $1,128 million, corresponding to a benefit-cost ratio of 1.40. This strategy would also result in a gain of 1,048 QALYs during the 180 days, indicating it was cost-saving. Probabilistic sensitivity analysis demonstrated that the probability of being cost-effective with the strategy was 68%. Further, vaccinating individuals aged 18-49 years with the second booster would result in an additional gain of $1,566 million and 2,276 QALYs. Expanding vaccination to individuals aged 12-17 years would result in an additional gain of $15 million and 89 QALYs. Coverage of the first booster vaccination in age groups under 12 was too low to consider the administration of the second booster. If the social interaction between all age groups was severed, vaccination expansion to 18-49yrs and 12-17yrs would no longer be cost-effective.Conclusion:
The second booster strategy was likely to be effective and cost-effective in reducing the disease burden of the COVID-19 pandemic. Expanding the second booster strategy to 18-49yrs and 12-17yrs remains cost-effective due to their social contacts with the older age group. Keywords COVID-19; Second booster; Cost-effective analysis; SEIR-Markov model; Age groups
Texte intégral:
Disponible
Collection:
Preprints
Base de données:
medRxiv
Sujet Principal:
COVID-19
langue:
Anglais
Année:
2022
Type de document:
Preprint
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS